Patents Assigned to John Wayne Cancer Institute
  • Patent number: 10987037
    Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: April 27, 2021
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventors: David Hoon, Bret Taback, Samuel Shaolian
  • Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • Patent number: 9567640
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 14, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9556491
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: January 31, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9410206
    Abstract: Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 9, 2016
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Laurent Lessard
  • Patent number: 9162884
    Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 20, 2015
    Assignee: John Wayne Cancer Institute
    Inventors: David Hoon, Bret Taback, Samuel Shaolian
  • Patent number: 9156898
    Abstract: The invention discloses a method of identifying a gene associated with stage III primary cancer or lymph node metastasis. The genes so identified include CAV1, CST3, LIMK1, MMP2, MMP15, VEGF, ETV4, MMP9, PIK3C2B, and SERPIN1. Also disclosed are methods for diagnosis, prognosis, and treatment of cancer. The invention further discloses compositions for preventing and treating diseases.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: October 13, 2015
    Assignee: John Wayne Cancer Institute
    Inventor: Richard Essner
  • Patent number: 9074253
    Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 7, 2015
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
  • Publication number: 20150176072
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 25, 2015
    Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
  • Publication number: 20150071852
    Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.
    Type: Application
    Filed: April 10, 2014
    Publication date: March 12, 2015
    Applicant: John Wayne Cancer Institute
    Inventor: Xiaojiang Cui
  • Publication number: 20140206961
    Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe.
    Type: Application
    Filed: October 28, 2013
    Publication date: July 24, 2014
    Applicant: John Wayne Cancer Institute
    Inventors: David Hoon, Bret Taback, Samuel Shaolian
  • Publication number: 20140134626
    Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: May 15, 2014
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
  • Publication number: 20130345144
    Abstract: Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 26, 2013
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Naoyuki Umetani
  • Patent number: 8569044
    Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: October 29, 2013
    Assignee: John Wayne Cancer Institute
    Inventors: David Hoon, Bret Taback, Samuel Shaolian
  • Publication number: 20130231259
    Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GaINAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GaINAcT, CK20, and ?-HCG.
    Type: Application
    Filed: December 11, 2012
    Publication date: September 5, 2013
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S.B. Hoon, Hiroya Takeuchi
  • Publication number: 20120295258
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Application
    Filed: May 11, 2012
    Publication date: November 22, 2012
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S.B. Hoon
  • Patent number: 8288099
    Abstract: The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: October 16, 2012
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Michiel de Maat
  • Publication number: 20120148561
    Abstract: The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S.B. Hoon, Minoru Kitago
  • Publication number: 20120088683
    Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
    Type: Application
    Filed: October 2, 2011
    Publication date: April 12, 2012
    Applicant: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Patent number: 8084246
    Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: December 27, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: David Hoon, Bret Taback, Samuel Shaolian